Ann: CEO Presentation - AGM 2017, page-20

I think most LBT investors would be more forgiving if management provided greater clarity and transparency in the moving of said goalposts. Milestones will always come and go with any company, targets are hit and miss due to internal and external factors, but LBT need to be clearer to maintain investor interest. A few things of note for me:
The language used in the announcement for the St. Vincent's trial was underwhelming, and failed to give me any indication that the hospital or LBT were excited by the results.
The was no reason given for the movement to CY 2018 for the European CE approval. What's the hold up?
The lack of information as to the extra time taken to secure distribution agreements in Europe.

For me the lack of detail will continue to hold back any sustainable SP appreciation....in many cases, this has become a longer term hold than many expected.